Opportunities and challenges for TCR mimic antibodies in cancer therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Opportunities and challenges for TCR mimic antibodies in cancer therapy

Published:2016-04-27 Issue:8 Volume:16 Page:979-987
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Chang Aaron Y.,Gejman Ron S.,Brea Elliott J.,Oh Claire Y.,Mathias Melissa D.,Pankov Dmitry,Casey Emily,Dao Tao,Scheinberg David A.

Funder

National Cancer Institute

National Institute of General Medical Sciences

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

http://www.tandfonline.com/doi/pdf/10.1080/14712598.2016.1176138

Reference57 articles.

1. Mass Spectrometry of Human Leukocyte Antigen Class I Peptidomes Reveals Strong Effects of Protein Abundance and Turnover on Antigen Presentation

2. Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6

3. Identification of α-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma

4. Antibody Targeting to a Class I MHC-Peptide Epitope Promotes Tumor Cell Death

5. Antibodies Directed Against the MHC-I Molecule H-2DdComplexed with an Antigenic Peptide: Similarities to a T Cell Receptor with the Same Specificity

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TCR-like bispecific antibodies toward eliminating infected hepatocytes in HBV mouse models;Emerging Microbes & Infections;2024-08-08

2. Dual-receptor T cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML;Blood Journal;2023-12-04

3. Conformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC enables targeting of WT1-pMHC low expressing cancer cells by anti-WT1-pMHC/CD3 T cell engagers;Frontiers in Immunology;2023-11-10

4. The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics;Chemical Reviews;2023-05-15

5. Cancer Immunotherapy: Where Next?;Cancers;2023-04-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3